Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as mometasone furoate dry powder inhaler
Mometasone Furoate Dry Inhaler · 1 trial · 1 indication
FEV1 (forced expiratory volume in one second) measurement at the Baseline visit was compared to the FEV1 measurement during the last visit at Week 12. The mean percent change was calculated.
| Arm | Type | Description |
|---|---|---|
| MF-DPI | EXPERIMENTAL | MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) |
| BUD-DPI | ACTIVE_COMPARATOR | Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) |
| Name | Type | Description |
|---|---|---|
| mometasone furoate dry powder inhaler | DRUG | MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks. |
| Budesonide DPI | DRUG | Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks. |
Inclusion Criteria: * Subjects must be 12 years of age or older of either gender, who (and their parent/guardian if the subject is under the age of 20) must demonstrate their willingness to sign and write informed consent. * Subjects must have had a history of asthma for at least 6 months. * The su...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Mometasone furoate dry inhaler is an investigational inhaled corticosteroid therapy being developed for asthma. It delivers mometasone furoate as a dry powder directly to the airways and is given as a 100 mcg dose. Organon & Co. (ticker OGN) is developing the product, which has completed Phase 3 clinical testing.
Mometasone furoate dry inhaler is being studied for the treatment of asthma. It is an inhaled corticosteroid formulated as a dry powder for delivery to the lungs. The clinical program enrolled adolescents and adults with asthma, with participants aged 12 years and older of any sex.
Organon & Co., which trades under the ticker OGN, is the developer of the mometasone furoate dry inhaler. The company is advancing the asthma asset, and the product is also referred to as mometasone furoate (MF) dry powder inhaler (DPI), 100 mcg.
Mometasone furoate dry inhaler is in Phase 3 development for asthma. It is an investigational product and is not described as approved. One Phase 3 trial has been completed, and no trials are currently listed as active. The completed study enrolled 180 participants.
Mometasone furoate dry inhaler has been evaluated in one completed Phase 3 trial, NCT00442117, titled A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Asthmatics (Study P04880). The randomized, active-controlled study enrolled 180 participants with asthma aged 12 years and older and has completed.